T1	Participants 691 762	patients with diabetes and A1C of >or=8-10% at randomization (n = 171),
T2	Participants 285 430	patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the MERLIN-TIMI-36 (MERLIN) study
